SLN News and Press, Silence Therapeutics Plc From 06/20/24

2024-06-20 15:30:05 ET Morgan Stanley analyst issues BUY recommendation for SLN on June 20, 2024 12:00PM ET. The previous analyst recommendation was Buy. SLN was trading at $18.9 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...

2024-06-20 11:17:44 ET More on Silence Therapeutics Silence Therapeutics reports Q1 results Seeking Alpha’s Quant Rating on Silence Therapeutics Historical earnings data for Silence Therapeutics Financial information for Silence Therapeutics ...

Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotec...

2024-06-03 01:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will presen...

2024-05-28 06:15:05 ET BMO Capital analyst issues OUTPERFORM recommendation for SLN on May 28, 2024 05:14AM ET. The previous analyst recommendation was Outperform. SLN was trading at $21.91 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-05-16 12:45:29 ET More on Silence Therapeutics Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript Silence Therapeutics plc 2023 Q4 - Results - Earnings Call Presentation Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Lo...

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results fo...

2024-05-14 03:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-07 17:26:02 ET More on Silence Therapeutics Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look Silence Therapeutics gains on mid-stage win for lead asset Seeking Alpha’s Quant Rating on Silence Therapeutics Read...